Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details
Open AccessResearch article

All-trans retinoic acid suppresses interleukin-6 expression in interleukin-1-stimulated synovial fibroblasts by inhibition of ERK1/2 pathway independently of RAR activation

Mélanie Kirchmeyer email, Meriem Koufany email, Sylvie Sebillaud email, Patrick Netter email, Jean-Yves Jouzeau email and Arnaud Bianchi email

Laboratoire de Physiopathologie et Pharmacologie Articulaires (LPPA), UMR 7561 CNRS-Nancy Université, 54505 Vandœuvre-lès-Nancy, France

author email corresponding author email

Arthritis Research & Therapy 2008, 10:R141doi:10.1186/ar2569

Published: 10 December 2008

Abstract

Introduction

Interleukin-6 (IL-6) is thought to play a pathogenic role in rheumatoid arthritis and synovium is a major source of IL-6 release. We investigated the ability of retinoids to suppress IL-6 expression in IL-1-stimulated synovial fibroblasts, with special care to the contribution of retinoic acid receptor (RAR) and retinoid X receptor (RXR) subtypes, and the implication of the mitogen-activated protein kinase (MAPK) pathway.

Methods

RAR-α, -β, and -γ and RXR-α, -β, and -γ levels were determined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) or Western blot in rat synovial fibroblasts stimulated with 10 ng/mL of IL-1β. Stimulated levels of IL-6 were assessed by RT-qPCR or immunoassays in the presence or absence of 1 μM all-trans retinoic acid (ATRA) (RAR agonist) or 0.3 μM BMS-649 (RXR agonist). The contribution of RAR subtypes was checked with selective agonists or small interfering RNAs. The effect of ATRA on upstream MAPK (p38 MAPK, c-Jun N-terminal kinase [JNK], and extracellularly regulated kinase 1/2 [ERK1/2]) was assessed by Western blot, and the contribution of the ERK1/2 pathway to the activation of pro-inflammatory transcription factors was studied by TransAm™ assays.

Results

Synovial fibroblasts expressed all RAR and RXR subtypes except RXR-γ. In IL-1-stimulated cells, ATRA, but not BMS-649, reduced IL-6 expression whereas selective RAR agonists were inactive. The inhibitory effect of ATRA on IL-6 was not affected by the silencing of RAR subtypes. ATRA also reduced the phosphorylation of ERK1/2, but not of p38 MAPK or of JNK. The suppressive effect of ATRA on the activation of activator protein-1 (AP-1) and nuclear factor-IL-6 (NF-IL-6) was reproduced by the MEK1 (mitogen-activated protein extracellularly regulated kinase kinase 1) inhibitor PD-98059, whereas ATRA and PD-98059 had no effect on NF-κB activation.

Conclusions

Among RAR and RXR agonists, only ATRA inhibited IL-1-induced IL-6 expression in rat synovial fibroblasts by inhibiting ERK1/2 pathway and subsequent activation of AP-1 and NF-IL-6 independently of RAR.


© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.